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FUNCTIONAL CONSEQUENCE OF PSAT1 ASSOCIATION ON PKM2’S 
INHERENT ENZYMATIC ACTIVITY 
Alexis Avidan Vega 
October 29, 2018 
Pyruvate kinase M2 (PKM2) is predominantly found in tumors, where it allows the 
cancer cell to adapt to metabolic conditions through allosteric regulation of its 
activity. We recently discovered that phosphoserine aminotransferase 1 (PSAT1) 
associates with and activates PKM2.  Here, I sought to affirm PSAT1's ability to 
increase PKM2 activity through kinetic and association studies of wild-type or 
mutant PKM2 enzymes. I demonstrate that His-tagged WT and mutant PKM2 
enzymes are active, exhibit different kinetics, yet cannot be activated by PSAT1. 
Comparison studies using untagged WT PKM2 suggest that inclusion of the His-
tag disrupts PSAT1 association. In support, pull-down strategies failed to 
demonstrate any PSAT1 interaction with the PKM2 proteins.  Future studies should 
focus on producing the PKM2 variants, potentially in untagged form, to assess their 
interaction with and activation by PSAT1.  These results would add to our 
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CHAPTER ONE: INTRODUCTION 
Glycolysis and Intermediary Metabolism 
 
 Adenosine Triphosphate (ATP) is the energy currency that is used by cells 
to perform many functions, such as macromolecular synthesis and size 
homeostasis.  In order to generate this energy, most mammalian cells metabolize 
sugars, notably glucose.  Glucose is a six-carbon sugar that is transported into the 
cell through various glucose transporters, termed GLUTs.  Once inside the cell, 
glucose carbons can be metabolized through various pathways within intermediary 
metabolism that gives rise to cellular components, including ATP, that is necessary 
for normal cell function (Figure 1).  Initially, glucose enters glycolysis, which was 
first described by Gustav Embden, Otto Meyerhof, and Jakub Parnas, that results 
in the formation of pyruvic acid.  Glycolysis can be divided into two sections: that 
requiring energy input and that resulting in energy production.   
 The initial reactions within glycolysis requires energy input in order to 
catabolize glucose.  Hexokinase (HK) transfers a phosphate group from ATP to 
glucose to generate glucose-6-phosphate (G6P).  This non-reversible step 
prohibits glucose from exiting the cell.  Next, phosphoglucose isomerase (PGI) 
isomerizes G6P into fructose-6-phosphate (F6P), which subsequently is 
phosphorylated in a non-reversible manner by ATP-demanding 




Figure 1. Schematic of glucose carbon fates through 
intermediary metabolism. Glucose can be fully oxidized within 
glycolysis and the TCA.  Glucose can also be metabolized in other 
pathways, such as the pentose phosphate pathway (PPP) and serine 
biosynthesis, to produce nucleic and amino acids for DNA/RNA and 
proteins, respectively. Lipids are generated through fatty acid 
synthesis from citrate-derived acetyl-CoA. Flux through these 
pathways is primarily controlled through activity of specific enzymes, 
including pyruvate kinase (PKM) and phosphoglycerate 
dehydrogenase (PHGDH).  




group from ATP to F6P to generate fructose 1,6-bisphosphate (FBP).  Aldolase 
then cleaves FBP, resulting in production of dihydroxyacetone phosphate and 
glyceraldehyde 3-phosphate (G3P).  Dihydroxyacetone phosphate and G3P 
isomerize between one another through the activity of triose phosphate isomerase.  
This energy-requiring segment of glycolysis utilizes 2 molecules of ATP for every 
1 molecule of glucose catabolized. 
 Subsequent to G3P are the energy producing reactions of glycolysis.  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) works to oxidize G3P into 
1,3-bisphosphoglycerate while also reducing nicotinamide adenine dinucleotide 
(NAD+) into NADH. Phosphoglycerate kinase functions to transfer a phosphate 
group from 1,3-bisphosphoglycerate to adenosine diphosphate (ADP) to produce 
ATP and 3-phosphoglycerate.  This is followed by conversion of 3-
phosphoglyerate into 2-phosphoglycerate by phosphoglycerate mutase.  Enolase 
then acts to remove a water molecule from 2-phosphoglycerate to generate 
phosphoenolpyruvate (PEP).  High energy PEP is then metabolized by pyruvate 
kinase (PK) to produce pyruvate, during which the high-energy phosphate group 
is transferred to ADP to form ATP.  Similar to HK and PFK1, PK is a non-reversible 
reaction and qualifies as the last step in the glycolytic pathway.  Within glycolysis, 
metabolism of one molecule of glucose generates a net gain of 2 ATP and 2 NADH. 
 Under normal aerobic conditions, pyruvate is converted into acetyl-CoA by 
pyruvate dehydrogenase that generates 1 NADH. Acetyl-CoA can then enter the 
tricarboxylic acid cycle (TCA) within the mitochondrial matrix.  Although the TCA 
contributes only one GTP molecule per turn, 3 molecules of NADH and 1 molecule 
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of reduced flavin adenine dinucleotide (FADH2) are produced. NADH and FADH2 
generated from glucose-derived pyruvate oxidation act as electron donors to 
acceptor complexes, such as cytochrome c oxidase, throughout the electron 
transport chain located within the inner mitochondrial membrane.  As these 
electrons traverse through the chain, ending in oxygen as a final acceptor, a proton 
gradient is formed across the mitochondrial inner membrane. This electrochemical 
gradient is then coupled to ATP synthesis by the flowing of protons through ATP 
synthase.  Under physiological conditions, each NADH yields 2.5 ATP, while 
oxidation of each FADH2 results in 1.5 ATP. Therefore, pyruvate oxidation 
generates 23 ATP from oxidative phosphorylation and 2 ATP from substrate level 
phosphorylation within the Kreb cycle. Coupled to the 2 ATP and NADH formed in 
glycolysis, each molecule of glucose can yield 32 ATP under normoxic conditions.  
In the case where sufficient oxygen is not available for cells to fully oxidize glucose 
(hypoxia), pyruvate can be fermented into lactic acid by lactate dehydrogenase 
(LDH).  Although fermentation does not contribute substrate level derived ATP, it 
is necessary to oxidize NADH back into NAD+ to allow glycolysis to continue [1]. 
In addition to hypoxia, other cellular alterations or pathologies also lead to 
enhanced glycolytic flux that promote either enhanced cell proliferation or survival.  
Glycolytic Shift in Tumor Cells 
 
 Flurodeoxyglucose positron emission tomography (FDG-PET) coupled with 
computed tomography (CT) is a tool used to screen for metabolically active cells 
in patients [2].  FDG is an analog of glucose wherein the hydroxyl located on 
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carbon 2 is substituted for a radiolabeled fluorine (18F).  Similar to glucose, FDG is 
taken in by the cells through glucose transporters and phosphorylated by HK that 
prevents it from escaping the cell.  However, the fluorine inhibits the cell from 
metabolizing phosphorylated FDG past this step [3-5].  PET imaging is then able 
to detect the radioisotopic fluorine accumulating in tissues [2, 6].  As one of the 
hallmarks of cancer is increased glucose metabolism, this procedure allows for 
diagnostic imaging in cancer patients [7, 8].  In addition, FDG-PET/CT can be used 
not only to initially detect tumor lesions but also monitor tumor response during 
treatment [9], which is why it has become the major clinical imaging tool in 
oncology. 
 It is well established that tumor cells take up glucose at a higher rate than 
non-tumor cells.  This change in glucose metabolism was first observed by Otto 
Warburg in the 1920s.  In his studies, less glucose was measured in outgoing 
blood vessels of tumor tissues compared with that of normal tissues [7].  The 
increase of glucose uptake also resulted in an increase of lactate production 
(fermentation), even in the presence of oxygen.  This ability for cancer cells to 
selectively metabolize glucose to lactate under normoxic conditions is termed 
aerobic glycolysis, or the “Warburg Effect” (Figure 2).  Warburg concluded that this 
deviation from normal glucose metabolism was brought upon by functionally 
impaired mitochondria in tumor cells [7, 10].  
Converse to Warburg’s idea that mitochondrial dysfunction was the primary 
causal shift towards aerobic glycolysis in tumor cells, it has now been established 




Figure 2. Representation of metabolic changes upon 
transformation from normal to cancer cell. Glucose is 
preferentially metabolized within the TCA for oxidative 
phosphorylation. However, cancer cells change their metabolism to 
increase production of macromolecules that are necessary for 
increased proliferation/growth. In addition, tumors secrete increased 
levels of lactate, even in the presence of oxygen, which helps 
promote invasion and metastasis.  
Schematic cited from Jó´zwiak P, Forma E, Bryma,M, andKrzek and 





example, knockdown of LDH-A increased mitochondrial respiration, leading to the 
conclusion that LDH-A was competing with the mitochondria for  glucose-derived 
pyruvate [11]. If the majority of tumor cells have functional mitochondria, other 
cellular forces must be promoting this metabolic shift towards aerobic glycolysis.  
One possible explanation for the Warburg effect could be the result of abnormal 
activation of certain genes, termed oncogenes, or inactivation of others, e.g. tumor 
suppressors [9, 11, 13].  Substantial work has now demonstrated the contribution 
of certain transcription factors or signaling pathways which control the Warburg 
Effect, including hypoxia inducing factor 1 (HIF1), MYC, and the AKT pathway 
[14, 15].  These pathways have been observed to alter the activity of certain 
glycolytic enzymes to increase glucose metabolism [14, 16, 17].  Among the 
enzymes that are direct targets of these upstream factors that increase glycolytic 
rate include GLUT1, HK, PFK, PK, and LDH [12, 18-24]. 
 Despite defining mechanisms as to how tumors increase glycolysis, the 
question remains as to why tumor cells would use such an inefficient technique to 
generate ATP.  It is now believed that tumor cells enhance their glycolytic rate, not 
for increased energy production, but because glycolytic intermediates are used to 
generate key components of proliferation [25].  For example, after glucose is 
converted into G6P in glycolysis, it can then be shunted into the Pentose 
Phosphate Pathways (PPP) (Figure 2).  Here, G6P continues to be metabolized to 
ultimately generate ribonucleotides and reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) [26-28]; both being necessary for cell 
proliferation [29].  The ribonucleotides produced by PPP are utilized to synthesize 
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nucleic acids, while the NADPH is consumed when producing fatty acids, 
cholesterol, and hormones.  NADPH is also required to re-establish reduced 
glutathione (GSH), which protects cells from reactive oxygen species (ROS) [30]. 
 Glycolytic intermediates may also feed into the serine synthetic pathway.  
Specifically, 3-PG is used as a substrate to produce 3-phosphohydroxypyruvate 
(PHP) through the activity of phosphoglycerate dehydrogenase (PHGDH).  
Phosphoserine aminotransferase 1 (PSAT1), with the co-factor pyridoxal 5’-
phosphate (PLP), transfers an amino group from L-glutamic acid to PHP.  This 
results in the production of phosphoserine (P-ser) and -ketoglutarate (KG).  
Phosphoserine phosphatase (PSPH) can then catalyze the reaction that removes 
an inorganic phosphate from P-Ser to produce serine.  While serine can be actively 
generated through this pathway, this non-essential amino acid can also be readily 
taken in from the extracellular environment [31]. 
 As an amino acid, one of the functions of serine is as a component of newly 
synthesized proteins.  In addition to this, serine can also be used to produce 
glycine through the transfer of one carbon to tetrahydrofolate (THF) to produce 
5,10-methylene-THF [31-34].  5,10-methylene-THF is required for the production 
of both purines and methionine [34].  Methionine can either continue on to be 
utilized as an amino acid for protein synthesis, or be used to produce S-adenosyl 
methionine (SAM) [31].  SAM is a substrate for methylation of DNA or RNA, as well 
as a precursor for production of homocysteine [35].  Homocysteine can then be 
used to produce GSH with the assistance of serine [31].  Given all of these cellular 
benefits to rapidly proliferate and protection against apoptosis, it is not surprising 
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that tumor cells upregulate enzymes found in the serine synthesis pathway [36, 
37]. 
Mediators of Altered Glycolysis and Tumorigenesis 
 
 With the increased availability of glycolytic intermediates, tumor cells can 
generate more biomolecular components for proliferation and cell survival.  This is 
accomplished by altering the rate of glycolysis through certain glycolytic 
isoenzymes.  GLUT1 is shown to be upregulated, which in turn increases the rate 
of glucose uptake [18].  Increased expression of HK2 in tumor cells can arise from 
both increased gene copy number or through direct transcriptional activation by 
oncogenes, such as c-Myc [24, 38]. Apart from increasing copy number or protein 
levels, increased glycolysis can occur through the utilization of small molecules 
capable of stimulating glycolytic enzymes.  Fructose 2,6-bisphosphate (F26BP) is 
one such small molecule known to stimulate PFK1.  By increasing PFK1’s affinity 
for F6P, F26BP allows for higher levels of glucose utilization  [19, 39-41].  Tumor 
cells also exhibit elevated expression of LDH [42], with the LDH-A isozyme being 
associated with metastasis and cell proliferation [11, 43, 44]. PK has also been 
shown to not only alter the rate of glycolysis, but also have other functions, which 
help facilitate the formation of tumors.   
 PK is known to have tissue-specific isoforms.  While PKL is expressed in 
liver tissues and PKR in erythrocytes, variants of PKM are found in all other tissues 
[45, 46]. Variants from the PKM gene can be divided into two groups: The M1 form 
found in the brain and skeletal muscles, and the M2 form found in remaining 
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tissues as well as in undifferentiated cells, such as embryonic cells [47].  As the 
PKM gene is responsible for encoding both isoforms, alternative splicing dictates 
which isoform is translated. 
 Of the exons within the PKM gene, it is the inclusion of either exon 9 or 10, 
and the exclusion of the other, that dictates the isoform produced (Figure 3).  Both 
exon 9 and 10 of the PKM gene encode for 56 amino acids. Of these, 34 are 
identical between exons while the remaining 22 are exclusive to their respective 
isoform [48, 49].  Under normoxic conditions, exon 10 is spliced out of the primary 
mRNA to produce PKM1.  The protein that is translated from this mRNA is 
observed as a fully active tetrameric protein.  However, under hypoxic conditions 
that are frequently seen within tumor cells, exon 9 is spliced out in preference for 
incorporation of exon 10 [48].  In addition to hypoxia, other cellular factors can 
promote this differential splicing. In particular, oncogenic c-Myc drives expression 
of heterogenous ribonucleoproteins (hnRNPs). HnRNPs are splicing factors that 
lead to alternative splicing for inclusion of exon 10 and expression of PKM2. 
Alternatively, inclusion of exon 10 can also be facilitated by other factors, including 
serine-argenine splice factor 3 (SRSF 3) [50-52].  These splicing mechanisms 
result in production of PKM2 that, in contrast to PKM1, is present as multiple 
oligomeric states: monomeric, dimeric, or tetrameric [46]. While discussed in more 
detail below, it has been demonstrated that PKM1 and PKM2 exhibit different 
levels of PK activity, with PKM2 being the least active. This finding has led to the 
postulation that tumor cells utilize the less active PKM2, due to its dimeric state, to 




Figure 3. Representation of PKM alternative splicing 
mechanisms that produces either PKM1 or PKM2. Both exon 
9 and exon 10 encode for 56 amino acids; of which, 34 are identical 
and 22 are exclusive to their respective isoforms. Inclusion of exon 9 
and exclusion of exon 10 results in expression of PKM1. However, 
oncogenic factors, such as c-Myc promote hnRNPs expression that 
suppresses splicing at exon 9 and results in incorporation of exon 10 
and exclusion of exon 9 from the final protein coding mRNA.  
Schematic cited from Nicholas Wong, Jason De Melo, and Damu 
Tang, ng, Tang, ng, De Melo, and Damu Tang, PKM2, a Central 
Point of Regulation in Cancer Metabolism . International Journal of 
Cell Biology, vol. 2013, Article ID 242513, 11 pages, 2013 
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above the PK step (Figure 4) [38].  These glycolytic intermediates can then be 
shunted to different pathways, which assists in cell proliferation and survival, 
including nucleotide biosynthesis stemming from pentose phosphate activity and 
one carbon metabolism driven by increased flux through the serine synthetic 
pathway. Beyond expression, allosteric regulation of PKM2 allows for “metabolic 
tuning” in such a way to either increase or decrease its activity (tetrameric versus 
dimeric), depending on the needs of the tumor cell (Figure 4) [53].   
 In the absence of any allosteric modulator, purified human PKM2 has been 
recorded to have a maximum velocity (Vmax) of 166.3mol/min and a Km for PEP 
of 0.86mM [46].  In contrast, PKM1, which primarily exists in a highly-active 
tetramer state, exhibits a Vmax of 345.6 mol/min and Km of 0.05mM for PEP.  One 
molecule that has previously been demonstrated to selectively increase PKM2 
activity is the glycolytic intermediate, FBP [54, 55]. Biologically, this allows for a 
forward feedback loop, wherein if glycolytic intermediates are in sufficient quantity, 
activation of PKM2 would result in further glycolytic flux and metabolism of glucose 
carbon into downstream processes.  The addition of FBP has been documented 
to promote the formation of tetrameric PKM2 from the available monomer/dimers 
[55]. This results in a modest increase in PKM2 activity (213 mol/min) and a 
significant decrease in Km for PEP to 0.10mM [46]. Unlike PKM2, PKM1 activity 
does not increase in the presence of FBP.  This is due to PKM1 being present 
exclusively as a tetramer.  Recently, it has been found that serine can also increase 
the activity of PKM2 [56-58].  Similar to FBP, serine induces strong tetramer 




Figure 4. Comparison between high active tetramer and 
low active dimer of PKM2. In the tetrameric form, PKM2 
catalyzes the reaction to produce pyruvate at a high rate for energy 
production.  In the dimeric form, the reaction rate of PKM2 is lowered 
that leads to accumulation of glycolytic intermediates which can be 
shunted to increase biomass and produce biomolecules useful in 
proliferation. 
Schematic cited from Witney, T.H., et al., PET imaging of tumor 
glycolysis downstream of hexokinase through noninvasive 




mechanism. As explained earlier, serine is derived from the glycolytic intermediate 
3-PG, which, if in excess, is shunted into the serine biosynthetic pathway. As 
serine levels become abundant in the cell, serine can activate PKM2 and lead to 
increased glycolysis and reduction in 3-PG levels. Although the binding pocket for 
serine can be found across different isoforms of PK, serine is unable to increase 
the activity of the M1 or L/R isoforms [56]. Contrary to FBP and serine, Christofk 
et al. demonstrated that phosphotyrosine peptides, of the tyrosine kinase signaling 
pathway, reduced the activity of PKM2 [59].  By acting as a competitor for FBP’s 
binding site, phosphotyrosine peptides can cause the dissociation of PKM2 and 
FBP.  The dissociation then results in PKM2 shifting back to a less active state.  
By doing so, the cell builds up the glycolytic intermediates to be shunted to multiple 
different pathways that can be used to facilitate proliferation.  
 A substantial amount of work has been done on defining the metabolic 
characteristics of PKM2, particularly as it relates to its pro-tumorigenic effects. Yet, 
more recently, studies have demonstrated that PKM2 exhibits non-metabolic 
functions that also may contribute to tumorigenesis. Outside of glycolysis, PKM2 
can act as a specific protein kinase or interact with other proteins.  Although 
normally located in the cytoplasm where it functions in glycolysis, PKM2 has also 
been seen to translocate into the nucleus [60].  While functioning as a protein 
kinase, PKM2 can phosphorylate Histone H3 on tyrosine 11 (H3T11) [60, 61] that 
leads to changes in gene expression, including Bub-3 for cell-cycle control [62], 
and B-cell lymphoma 2 (BCL-2) to prevent apoptosis [63].  In addition, nuclear 
PKM2 directly associates with β-catenin and assists in transactivating downstream 
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target genes, such as c-Myc and CCND1 (encodes for cyclin D1) [60, 61]. Within 
the nucleus, PKM2 can also interact with several other proteins such as HIF-1, 
octamer-binding transcription factor 4 (Oct-4), and suppressor of cytokine 
signaling 3 (SOCS3) to act as a coactivator for gene expression [60, 64-66]. Taken 
together, prior studies have emphasized the relevance of PKM2 in contributing to 
tumorigenic growth, not only from its altered activity within glycolysis, but as an 
important mediator in promoting gene expression through its non-canonical protein 
kinase and protein:protein interactions. Therefore, identifying additional binding 
partners may provide further insight into the unique function of PKM2 in cancer.    
 
PSAT1 as a Novel PKM2 activator 
 
 Activity within multiple biochemical pathways are changed in response to 
tumor initiation and progression. Among these, enhanced flux within serine 
metabolism has been demonstrated in tumors from various tissue types. Previous 
studies have attempted to understand the pro-tumor advantage for increased 
serine production in various cancers, such as breast and lung [67, 68]. Serine 
metabolism provides amino acids for protein synthesis and promotes one carbon 
metabolism through formation of methyl-tetrahydrofolate (mTHF) from the 
conversion of serine to glycine. mTHF is a precursor required for novel nucleotide 
production, which is necessary for rapidly proliferating cells. In addition, the 
aminotransferase reaction of PSAT1 promotes glutamine metabolism as a source 
of anaplerotic carbon for the TCA cycle through the conversion of glutamate to 
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αKG [67]. This elevated serine biosynthetic activity observed in tumors is 
accomplished through increased expression of enzymes within this pathway, 
including PSAT1 (Figure 5).  
 Prior attempts to understand the relevance of serine synthetic enzymes, 
including PHGDH and PSAT1, in tumor progression has been done using knock-
down strategies in tumor cells. Within breast cancer cells, reduction of either 
PSAT1 or PHGDH reduced cell proliferation, which could be partially rescued by 
addition of downstream metabolites, such as αKG, non-essential amino acids, and 
nucleosides to the culture medium [69].  Yet, this result is somewhat surprising in 
that serine can be actively taken up from the outside environment and presumed 
to be utilized in an identical manner as synthesized serine. While some progress 
has been made in identifying requirements for serine synthesis in promoting tumor 
progression, the relevance for this pathway is not completely understood. Multiple 
metabolic enzymes, such as enolase and PKM2, have been identified to have 
alternative functions, including protein-protein interactions. We postulated that 
enzymes within the serine biosynthetic pathway, specifically PSAT1, may have 
unknown binding partners. In addition to its role in serine production, these 
interactions may also promote pro-tumor activities.  
 To identify potential protein: protein associations with PSAT1, the Clem lab 
performed a pull-down experiment incorporating protein lysates from A549 lung 
cancer cells and GST-tagged PSAT1 bound to a glutathione bead column. Mass 
spectrometry analysis of specific associating proteins identified PKM as a new 
interacting protein of PSAT1.  As the peptide fragments did not distinguish between 
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PKM1 or PKM2 (coverage only in identical amino acid regions of both proteins), 
co-immunoprecipitation (Co-IP) analysis was done using purified commercially 
available (Sigma) untagged purified PKM1 (PKM1-Sigma) and PKM2 (PKM2-
Sigma) with untagged PSAT1 that was produced and purified within the Clem lab.  
 To understand a potential biological effect of this interaction, in-vitro 
enzymatic assays were done to determine if this interaction had any effect on 
pyruvate kinase enzyme activity. Activity of PKM1-Sigma and PKM2-Sigma were 
done in the absence or presence of PSAT1 using an end-point activity assay 
(Kinase ADP Glo).  As PK generates ATP from ADP, ATP generates light, through 
luciferase-mediated conversion of luciferin to oxyluciferin, which is presented as 
relative light units.  Using this approach, addition of PSAT1 resulted in a dose-
dependent increase in PKM2-Sigma activity up to four-fold activation in the 
presence of 400nM PSAT1. PSAT1 failed to increase PKM1-Sigma activity at any 
concentration. To address whether the native PSAT1:PKM2 interaction is 
promoting the increase in activity, an aliquot of PSAT1 was boiled to denature the 
protein before addition to the enzyme assay. Loss of native formation of PSAT1 
failed to activate PKM2-Sigma, suggesting that it is the protein-protein interaction 
selectively with PKM2 that is promoting pyruvate kinase activity.  
 To initially understand which domains or amino acids within PKM2 may be 
responsible for interacting with PSAT1, a computational comparison was done 




changes between incorporation of exon 9 (PKM1) or exon 10 (PKM2) are localized 
within a loop structure on the external region of the PKM protein (Figure 6A, 
illustrated in cyan on left side of crystal structure). This suggested that this site may 
be the region responsible for the PKM2:PSAT1 interaction. To test the amino acids 
within this region that may contribute to PSAT1 interaction, we randomly mutated 
separate amino acids within the non-synonymous region to those amino acids 
found in PKM1 (Figure  6B). Four distinct site-specific mutants were constructed: 
Mutant 1 (MT1) containing L391R and Q392K, Mutant 2 (MT2) containing P402S 
and I403H, Mutant 3 (MT3) containing P402S, I403H, and R398V, and Mutant 4 
(MT4) containing R398V.  To avoid the potential for dramatic changes in the PKM2 
structure upon mutation, the amino acid modifications were constructed in order to 
revert those amino acids to those found in PKM1. FLAG-tagged constructs 
encoding WT or the mutant PKM2 proteins were expressed in HEK293T cells and 
immunoprecipitated using anti-FLAG antibody conjugated sepharose beads. 
Immunoblot analysis of immunoprecipitated complexes found that while PKM2 
Wild-Type (WT), MT1, MT2 and MT4 interacted with PSAT1, amino acid changes 
in MT3 resulted in loss of PSAT1 association.  
 We hypothesize that PKM2 mutations will abolish activation by PSAT1 
through disruption of the PSAT1:PKM2 interaction.  However, these data do not 
exclude the possibility that the point mutations change the overall structure of PK 
and contribute to the loss of binding.  Furthermore, it is plausible that the mutations, 
alone, could alter the activity of PK in such a way to differ from the wild-type 





Figure 5.  Schematic of serine metabolism.  Serine is be 
synthesized from the glycolytic intermediate 3-
Phosphoglycerate.  Synthesis of serine leads to the production 
of alpha Ketogluterate, which can go on to enter the carboxylic 
acid cycle.  Serine can also be metabolized by cells to 
synthesize nucleotides.  Schematic edited from: Cancer's sweet 
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Figure 6.  Superimposed crystal structures of PKM2 and 
PKM1 identify region of divergent sequence. A) Crystal 
structure of PKM2 (cyan) overlaid atop the crystal structure of 
PKM1 (blue).  PKM2 contained an outer looped region (“) that 
was not shared with PKM1.  B) Mutations on PKM2, reverting 
the amino acid on PKM2 WT to those seen in PKM1.  Mutation 
sites colored in red and highlighted in gray 
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in the presence or absence of PSAT1 (Aim1) and assess the direct interaction with 
recombinant WT and MT(1-4) PKM2 with PSAT1 (Aim2).  Completion of these 
studies aims to define the kinetic parameters of WT and MT(1-4) PKM2, PSAT1’s 





CHAPTER TWO: MATERIALS AND METHODS 
Vector Generation 
 Plasmids containing cDNA encoding WT or mutant PKM2 was generously 
provided by Rumeysa Biyik-Sit for construction of these expression vectors. 
cDNAs for PKM2-WT, -MT1, -MT2, -MT3, or -MT4 were sub-cloned from the 
provided pcDNA3.1 vector into either the pGEX-4T-1 (GST-fusion) or pET30a (His-
fusion) expression plasmids. Briefly, 1g of plasmid was incubated at 37oC for 15 
minutes in a solution containing 2L of Fast Digest Buffer, 1L of BamHI, 1L of 
EcoRI, and brought up to 20L with Nuclease-Free water.  Subsequently, the 
digestion reactions were loaded onto a 1% agarose gel and ran for 30 minutes at 
100V.  Bands corresponding to cut destination plasmids (pGEX-4T-1 or pET30a) 
or PKM2 cDNA were excised from the gel and centrifuged through a Gen Elute 
Agarose Spin Column (Sigma Cat#56500) at 18,000 x g for 10 minutes.  The elute 
was then ethanol precipitated by addition of 1% of 3M sodium acetate at pH 5.2 
and 2.5 x volume of absolute ethanol and incubated for 20 minutes at -80oC.  The 
solution was centrifuged for 20 minutes at 4oC and 12,000 rpm.  The supernatant 
was removed, and the pellet was washed with 500L of 70% ethanol.  Centrifuge 
was repeated to remove the supernatant and any excess ethanol.  The pellet was 
resuspended in 10L of Nuclease-Free water.  The concentration of DNA was 
taken by nanodrop.  Molar ratio of 1:1.73 insert to vector DNA was incubated
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 overnight at 4oC in a solution containing 1L of ligase buffer, 1 unit of T4 DNA 
Ligase, and brought up to 10L with water.  
Transformation of bacterial cells 
1L of ligation mixture was added to one vial of TOP10 DH5α competent cells and 
incubated on ice for 30 minutes.  Cells were then heat-shocked for 30 seconds at 
42oC and immediately transferred to ice and incubated for an addition 2 minutes. 
250L of S.O.C medium was added to the bacterial solution and incubated at 37oC 
for 1 hour.  Bacterial cells were spread onto LB plate containing appropriate 
antibiotics and incubated overnight at 37oC.  Cells transformed with pGEX4T-1 
were spread onto a plate containing ampicillin; cells transformed with pET30a were 
spread onto a plate containing kanamycin. 
Construct Verification 
 A single bacterial colony was harvested from the transformed LB agar plate 
and grown in 5mL of LB containing appropriate antibiotic overnight at 37oC.  
Bacterial cells were pelleted by centrifugation for 3 minutes at 8,000 rpm, and 
plasmid DNA was purified using plasmid miniprep kit following the manufacturer’s 
protocol (Qiagen Cat#27106) [ref: QIAprep® Miniprep Handbook 2nd Edition. May 
2012.  Available: 
https://www.qiagen.com/us/resources/resourcedetail?id=89bfa021-7310-4c0f-
90e0-6a9c84f66cee&lang=en.].   
 Plasmid DNA was then sequenced to verify incorporation of WT or MT 
PKM2.  For pGEX4T-1 vectors, 250ng of plasmid DNA was combined with either 
2L of Forward Sequencing Primer (5’-
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GATCGAATTCATGTCGAAGCCCCATAGTGAAG-3’) or 2L of Reverse 
Sequencing Primer (5’-CTGGGGATCCTCACGGCACAGGAACAACACGC-3’).  
Samples were then sent to Eurofins Genomics to be sequenced.  For pET30a 
vectors, 250ng of plasmid DNA was sent to Eurofins Genomics to be sequenced 
using company provided T7 and T7 Terminator primers. Sequences were then 
assessed through a BLAST search to verify presence of the respective PKM2 
cDNAs and to ensure that each was incorporated into the plasmid in the correct 
orientation and in-frame. 
Expression of Recombinant GST-PKM2 Proteins 
 A single colony of transformed bacteria was grown in a sterile Erlenmeyer 
flask, containing 100mL of LB and 100ug/mL of Ampicillin, and incubated overnight 
at 37oC.  100mL of fresh LB and ampicillin was added to the starter culture and 
incubated at 37oC for an additional 3 hours.  When the bacterial culture reached 
an OD600 of ~ 0.7, IPTG was added to final concentration of 1mM and incubated at 
37oC for additional 4 hours.  Bacterial cells were then pelleted and stored, 
overnight, in -80oC.  The pellet was thawed and resuspended with 4mL of B-PER 
lysis buffer (Pierce, containing 2L of lysozyme, 2L of DNase I, and 10L of 
Protease Inhibitors for every 1 mL of B-PER buffer) for every gram of bacterial 
pellet. The resuspended pellet was incubated for 15 minutes at room temperature 
followed by centrifugation for 5 minutes at 15,000 x g in 4oC to obtain bacterial 
lysate. 
GST-PKM2 Protein Purified by Affinity Chromatography 
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 Glutathione sepharose containing spin-columns were washed twice with 1X 
PBS and centrifuged at 700 x g for 2 minutes at 4oC. Bacterial lysates were added 
to columns and incubated for 60 minutes at 4oC on a rocking platform, followed by 
centrifugation at 700 x g.  The flow-through was collected and saved for further 
analysis.  Columns were washed 3 additional times with PBS, with an aliquot of 
each wash being saved for future analysis.  1mL of Glutathione Elution buffer 
(50mM Tris HCl, 10mM reduced glutathione, and adjusted to pH 8.0) was added 
to each column and incubated overnight at room temperature.  Columns were 
centrifuged to collect eluted protein and repeated 2x using fresh elution buffer.  The 
reduced glutathione was removed from the elution fraction through dialysis with 
1000X volume of buffer containing: 25mM of Tris HCl at pH 7.4, 100mM of KCl, 
5mM of MgCl2, and 10% glycerol for 2 hours at 4oC.  The buffer was changed, and 
dialysis was continued for an additional 16 hours at 4oC. 
Expression and purification of His-tagged PKM2 Proteins 
 Expression and purification of His-tagged PKM2 variants was performed 
following the same procedure as that for GST-tagged PKM2 with minor 
modifications. Briefly, the frozen pellet was thawed at room temperature for 15 
minutes followed by incubation in 5mL of Binding Buffer (50mM Tris HCl pH 8.0, 
10mM MgCl2, 300mM NaCl, 5mM Imidazole, 10% Glycerol) containing 10L 
lysosome and 10L of DNase for 15 additional minutes.  Lysates were then 
sonicated 3X in 15 second intervals and added to pre-washed Ni-NTA beads 
overnight in 4oC.  Poly prep chromatography columns were washed the following 
day 2X with 5mL of Washing Buffer (50mM Tris, 10mM MgCl2, 300mM NaCl, 
26 
 
30mM Imidazole, 10% glycerol) prior to the addition of lysate/bead mixture.  The 
resin was washed 4 times with Wash Buffer followed by incubating columns at 
room temperature with 1 mL of Elution Buffer (50mM Tris, 10mM MgCl2, 250mM 
NaCl, 250mM Imidazole, and 10% glycerol) for 1 hour. Aliquots of starting lysate, 
washes and elutions were collected and stored for future analysis. Imidazole was 
removed from elutions through dialysis using 50mM Tris, 10mM MgCl2, 25mM 
NaCl, and 10% glycerol overnight at 4oC.  Protein concentration was determined 
by Nanodrop, and subsequently aliquoted, flash-frozen in LN2, and stored in -80°C. 
Coomassie Stain 
 Aliquots from bacterial lysates, column washes, and dialyzed elutions were 
assessed for protein content and purity by Coomassie stain.  Samples were loaded 
onto 10% SDS-Polyacrylamide Gel Electrophoresis (PAGE) gel and ran for 30 
minutes at 200V.  The SDS-PAGE gel was then stained with Coomassie Brilliant 
Blue R250 Stain for 30 minutes.  The stained gel was then washed with a de-stain 
solution containing 10% acetic acid, 20% methanol. 
Immunoblotting 
 Protein samples were mixed 1:1 with 2X SDS-sample buffer and separated 
by 10% SDS-PAGE at 200v for 30 minutes. Proteins were then transferred to 
PVDF membrane in transfer buffer for one hour at 200v. Membranes were 
incubated in blocking buffer (5% non-fat dry milk in TBS-Tween) for one hour. 
Primary antibodies at defined dilutions were placed on membranes overnight at 
4°C with constant rocking. After 3X washes with TBS-Tween, membranes were 
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incubated with appropriate secondary antibodies and protein was detected using 
ECL chemiluminescent reagent.  
Antibodies 
 For Western blot analysis, membranes were probed with 1:1000 anti-HIS 
(Cell Signaling; 12698S), anti-PKM2 (Cell Signaling; 4053S), or anti-PSAT 
(ProteinTech; 20180-1-AP). Anti-rabbit HRP-linked secondary antibody (1:5000; 
Thermo; 31460) was used to detect proteins.  
Protein Cross-Linking 
 Disuccinimidyl suberate (DSS) cross-linking agent was reconstituted to 
25mM in DMSO. 50ng of recombinant His-PKM2 WT, MT1, MT2, MT3, or MT4 
was diluted in 60μL 1X PBS with subsequent addition of DSS to a final volume of 
10 or 20μM. Samples were then incubated for 15 minutes at 37°C. To stop the 
cross-linking reaction, Tris (pH 7.4) was added to a final concentration of 50mM 
and incubated for 15 minutes at room temperature. 60L of 2X sample buffer was 
added to the reaction and heated for 5 minutes at 95°C. 30L of sample was 
separated by SDS-PAGE and oligomeric state of PKM2 was determined by 
immunoblot analysis.   
PKM2 Kinetics Assay 
 Enzyme kinetics of PKM2 WT and mutant proteins were determined using 
an LDH enzyme coupled assay. PKM2-derived pyruvate is rapidly converted by 
LDH to lactate with equimolar oxidation of NADH to NAD+. For the assay, a 10x 
Reaction Buffer stock was made containing 500mM Tris HCl pH 8.0, 500mM KCl, 
and 50mM MgCl2.  Assay master mixes were generated containing a final 
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concentration of 1X Reaction Buffer, 0.6 mM ADP, 0.54 mM NADH, 0.016g/uL 
LDH, and different concentrations of PEP ranging from 0.025 to 4mM.  100L of 
assay solution was then aliquoted into a 96-well plate in triplicate for each PEP 
concentration.  Separately, PKM2 enzymes were incubated with or without 400nM 
PSAT1 or 500M FBP in 1X reaction buffer for 30 minutes at 37°C. To initiate the 
kinetic reaction, PKM2 samples were then added to the assay solution to a final 
concentration of 2.5nM PKM2. NADH absorbance was recorded at 340nm every 
30 seconds for 10 minutes using a Biotek spectrophotometer plate reader.  
Absorbance readings were plotted against time and rates of NADH consumption 
(OD/min) at each PEP concentration were determined by the slope of linear 
equation. Rates were then converted to μmol/min using the NADH extinction 
coefficient (6220M-1cm-1). Initial velocities were then plotted against each PEP 
concentration and kinetic parameters (Vmax and KM) of each PKM2 protein with or 
without PSAT1 or FBP were determined by non-linear regression analysis using 
Prism software.   
Pulldown Assay using His-PKM2 
 500ng of PSAT1 was incubated with 50ng of WT or mutant His-PKM2 in 
500L of Binding Buffer for 45 minutes at 4oC.  30L of Ni-NTA sepharose bead 
slurry was washed with Washing Buffer, reconstituted in 0.1% BSA and incubated 
for 1 hour at 4oC.  Beads were then added to the His-PKM2:PSAT1 solution and 
incubated overnight at 4oC.  Ni-NTA beads were centrifuged and washed twice.  
30L of 1x Laemmli Sample Buffer was added to the Ni-NTA beads and heated at 
95oC for 5 minutes The supernatant was then loaded onto an SDS-PAGE and 
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presence of PSAT1 and PKM2 were analyzed by immunoblotting using anti-His or 
anti-PSAT1 antibodies.  
Co-Immunoprecipitation of His-PKM2:PSAT1 
 50ng of PSAT1 and 500ng WT or mutant His-PKM2 was incubated in 500L 
of Lysis Buffer at room temperature for 45 minutes.  1g of anti-PSAT1 antibody 
or control IgG was added to the protein mixture and incubated overnight at 4oC.  
Protein G Dynabeads (Invitrogen) (50L per immunoprecipitation) were washed 
twice in 250L of Ab Wash Buffer, resuspended in Antibody binding buffer 
(Invitrogen) and added to protein samples for 45 minutes at room temperature with 
end-over-end rocking.  Immunocomplexes were collected by placement on 
Magnarack (Invitrogen) and subsequently washed 3 times with 200L of Wash 
Buffer. 25L of 1x Laemmli Buffer was added to the beads and incubated at 95oC 
for 3 minutes.  Solution was placed back on Magnarack for 2 minutes, and protein 
supernatant was separated by SDS-PAGE. Presence of PSAT1 and PKM2 were 
assessed by immunoblotting using anti-PSAT1 or anti-His antibodies. 
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CHAPTER THREE: RESULTS  
Expression of GST-PKM2  
The initial objective of these studies was to recombinantly express and 
purify PKM2 WT and PKM2 variants harboring the mutations indicated in Figure 7. 
Previous reports have demonstrated that utilizing a GST-fusion system could 
assist in properly folding proteins that are prone to aggregation [70]. I chose to 
express PKM2 as a GST-fusion protein utilizing the pGEX4T-1 vector system that 
encodes a GST-tag on the N-terminus of the fusion protein.  cDNAs encoding WT, 
MT1, MT2, or MT3 were previously generated within the lab using site-directed 
mutagenesis and sequenced to verify correct mutational status (Figure 7A-D). 
Each cDNA was sub-cloned into the pGEX4T-1 vector and underwent DNA 
sequencing and subsequent BLAST search to ensure correct orientation and 
presence of mutations. 
Purification of GST-PKM2 
Plasmids that had been verified to encode WT or mutant GST-PKM2 were 
transformed into BL21(DE3) cells.  Following the protocol outlined by Park et al. to 
increase yield of GST-fusion proteins [72], I initially attempted to purify WT GST-
PKM2 using a Sarkosyl: Triton X100 buffer for bacterial extraction [73].  PKM2 has 
a molecular weight of 56 kDa, and with the addition of the GST-(27kDa), the fusion 
protein is expected to have a molecular weight of ~80 kDa. While I was able to 









Figure 7.  Sequence analysis of cDNA encoding WT and mutant 
variants of PKM2 Plasmid DNA was commercially sequenced by Eurofins 
Genomics. Computational BLAST analysis revealed correct orientation and 




GST-PKM2 was collected from the glutathione beads as demonstrated by SDS-
PAGE and Coomassie stain (Figure 8).  I then attempted an alternative strategy 
for protein purification using the Tris-based B-PER solution (Bacterial Protein 
Extraction Reagent, ThermoFisher).  Utilizing this bacterial lysis protocol followed 
by glutathione bead affinity chromatography, I was able to recover GST-PKM2 WT, 
MT1, MT2, and MT3 (Figure 9). 
 
Enzymatic Activity of GST-PKM2   
 To determine whether the GST-PKM2 enzymes had activity, I utilized an 
enzyme-coupled assay incorporating LDH-mediated consumption of NADH 
(Figure 10A).  As PKM2 generates pyruvate from PEP, LDH subsequently 
metabolizes pyruvate to lactate while simultaneously converting NADH to NAD+, 
in an equal mole to mole ratio. Loss of NADH absorbance in a linear fashion allows 
for the indirect measurement of PKM2 activity.  Using this approach, I recorded no 
enzymatic activity above background with any of the GST-PKM2 enzymes (WT, 
MT1, M2 or M3) at 0.5 mM PEP (Figure 10B). To ensure the functionality of the 
enzyme assay, I included untagged PKM2-Sigma as a positive control.  As shown 
in Figure 11B, PKM2-Sigma exhibits pyruvate kinase activity based on the linear 
consumption of NADH. The lack of activity of the GST-PKM2 proteins suggest that 
the addition of the large GST tag at the N-terminus of PKM2 may be inhibiting the 
catalytic activity of the enzyme. 
  




Figure 8. Extraction of GST-PKM2 WT from bacterial 
lysates using ionic detergent (Sarkosyl). Wild-type GST-
PKM2 expression in transformed BL21 cells was induced with IPTG 
as described in the materials and methods. Cell pellet was then 
extracted using Sarkosyl-Triton X-100 buffer and proteins purified 
by glutathione elution from glutathione linked sepharose beads. 
Lysates or elutions from induced and non-induced bacteria were 







Figure 9.  Purification of GST-PKM2 enzymes using an alternative 
extraction protocol. Expression of fusion GST-PKM2 proteins in 
transformed BL21 cells was induced by IPTG as described in the materials and 
methods. Proteins were extracted using B-PER buffer (Thermo Fischer) with 
addition of DNase and lysozyme. GST-PKM2 proteins were purified by 
glutathione elution from glutathione-linked sepharose beads. Lysates and 
elutions (GST-PKM2) were subjected to SDS-PAGE and Coomassie stain. 

























































Figure 10.  Kinetic analysis of GST-PKM2 recombinant enzymes. (A) 
Scheme of the LDH-coupled assay used to measure PKM2 activity through 
consumption of NADH, which is assessed by loss of NADH absorbance at 
340nm. (B) Representative kinetic assay comparing WT, MT1, MT2, and MT3 
GST-PKM2 at 4nM protein concentration and 0,5mM PEP. Data is 
demonstrated as loss of absorbance of NADH at 340nm over time. Addition of 




To determine whether the GST-tag was responsible for the inactivity of 
PKM2, I attempted to purify PKM2 from induced GST-PKM2 bacteria lysates  
through removal of GST-tag by thrombin cleavage.  The pGEX-4T-1 vector 
encodes a thrombin cleavage site between the GST-tag and the N-terminal amino 
acid of PKM2.  After the final wash during glutathione-sepharose purification, I 
incubated protein-bound beads for 45 minutes at room temperature with Thrombin 
protease to release cleaved PKM2 from the bead matrix. SDS-PAGE and 
Coomassie stain analysis of cleaved elutions revealed no recovery of PKM2 
protein (Figure 11).  Together, these data indicate that while my experimental 
conditions are sufficient to express WT and MT GST-PKM2 proteins, they are 
inactive and thrombin cleavage under these conditions is ineffective in recovering 
PKM2 enzymes.  
PKM2 was sub-cloned into a pET vector encoding a smaller fusion tag 
 To circumvent the potential issue of the large GST tag affecting PKM2 
activity, I decided to use a different protein fusion expression system. The PKM2 
cDNAs were sub-cloned into the pET30a vector, which encodes for a small 6x His-
tag at the N-terminal end of the fusion protein (1kDa compared to 27kDa GST-
tag). Initially, I utilized the extraction protocol for the GST-fusion proteins discussed 
above (ie buffer conditions) in conjunction with affinity purification with imidazole 
elutions from Ni-NTA beads. SDS-PAGE analysis demonstrated large amounts of 




   
Figure 11.  Thrombin cleavage of recombinant GST-PKM2 proteins. 
Bacterial lysates induced for GST-PKM2 WT, MT1, MT2, and MT3 were 
incubated with glutathione sepharose. Immobilized GST-PKM2 enzymes were 
treated with thrombin in order to cleave the GST-tag from the recombinant 
protein and result in PKM2 elution from the column matrix. Bacterial lysates or 






































Figure 12.  Purification of His-tagged PKM2 proteins. (A) Initial 
purification of His-WT PKM2 from IPTG-induced BL21 cells with Ni-NTA 
sepharose resulted in the presence of higher molecular weight proteins upon 
elution with imidazole. (B) Optimization of expression/extraction protocol led to 
purification WT, MT1, MT2, and MT4 His-PKM2 from Ni-NTA sepharose. 
Aliquots from lysates, washes, or imidazole elutions were subjected to SDS-
PAGE and Coomassie staining. Expected molecular weight of His-PKM2 is 





unable to discern the presence of any His-PKM2 protein.  I further developed the 
purification protocol for the His-PKM2 proteins by changing the extraction/binding 
buffers and the addition of sonication to the bacterial lysates. After optimization, I 
was able to recover His-PKM2 WT, MT1, MT2, MT3, and MT4 to greater than 95% 
purity (Figure 12B, only WT, MT1, MT2, and MT4 are shown). I have noticed that 
His-PKM2-MT4 consistently resulted in lower yield compared to the other samples, 
but this may be due to lower overall extracted proteins in bacteria (Figure 12B). 
Kinetic Analysis of His-PKM2 Enzymes  
To determine that the protein concentration to be used in the kinetic analysis 
would be within a linear relationship of initial velocity and enzyme concentration, I 
first measured initial velocities (mOD absorbance / min) within a range of His-
PKM2 concentrations, from 1.0 to 4.0nM of the enzyme. Unlike the GST-PKM2 
enzymes, I found that His-PKM2 proteins showed activity within the LDH coupled 
assay (Figure 13 A-C; data shown for PKM2 MT1, MT2, and MT4). From these 
studies, I selected 2.5 nM as an optimal concentration for kinetic characterization 
of these enzymes (Figure 13A-C). Western blot analysis was also performed 
comparing His-PKM2 proteins across separate preparations [Batch 1 (B1) or Batch 
2 (B3)] to ensure that they were similar across all samples (Figure 14 A-B). 
I next proceeded to measure His-PKM2 activity, using 2.5nM of each 
enzyme, across multiple concentrations of PEP, ranging from 0.025mM to 4mM. 
Using the NADH extinction coefficietny, the initial linear slope of NADH 
consumption (mOD / min) can be converted to an initial velocity kinetic rate for 








Figure 13. Kinetic analysis to determine optimal PKM2 
concentration. Rates of NADH consumption was measured under increasing 
concentrations of His-PKM2.  Depicted are the reads from MT1 (A) MT2 (B) and 
MT4 (C).  Points were plotted based on mOD/min and were fit to linear 






























Figure 14.  Kinetic analysis of WT or MT His-PKM2 enzymes.  His-tagged 
WT, MT1, MT2, MT3, and MT4 PKM2 were purified using Ni-NTA as described in the 
materials and methods (A & B) Western blots of His-PKM2 proteins from Batch 1 and 
2 were performed to aid in concentration adjustments for the kinetic assays. (C) 
Average initial velocities of the His-PKM2 proteins (2.5nM) in the presence of 
increasing concentrations of PEP. Data is represented as nmol / min and fitted to a 
non-linear regression analysis. Results are an average of two experiments using 
protein preparations from either batch 1 or batch 2 that incorporate two technical 
replicates. Average kinetic parameters (Vmax and Km) for each enzyme is detailed 
within the table with the standard deviations indicated within the parentheses.   
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  Figure 15.  Vmax differences between His-PKM2. 
Comparison of calculated Vmax values across wild-type or 
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  Figure 16.  Km differences between His-PKM2.  Calculated 
Km values of His-PKM2 WT, MT1, MT2, and MT4. 
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velocities (nmol / min) were plotted versus PEP concentration for the WT and MT 
His-PKM2 proteins from both preparations (Figure 14C; plots for each individual 
enzyme are shown in Appendix Figures 29-36). Non-linear regression analysis 
was used to determine both the maximum velocity (Vmax) and Michaelis-Menten 
constant (Km) for each enzyme.  The calculated average Vmax for WT, MT1, MT2, 
and MT4 His-PKM2 were 0.77, 0.76, 1.3, and 0.49 (nmol / min), respectively. The 
Km values for WT, MT1, MT2, and MT4 His-PKM2 were determined to be 0.28, 
0.75, 0.39, 0.70 mM (Figure 14C), respectively.  No activity was detected for His-
PKM2 MT3 across any concentrations of PEP.  The specific activity of human WT 
PKM2 has been previously reported as 116 μmol/min/mg protein [47]. His-PKM2 
WT used in these studies exhibited a specific activity of 55 μmol/min/mg. 
Comparison of activity of His-PKM2 WT to mutant enzymes indicate that mutations 
within MT1 did not alter Vmax, yet amino acid changes within MT2 led to an increase 
in Vmax (Figure 15). In addition, mutation of a single amino acid in His-PKM2 MT4 
resulted in decreased activity. While not significant, mutations in either His-PKM2 
MT1 or MT4 appeared to increase the Km for PEP compared to WT (0.28 vs. 
0.75mM or 0.70mM, respectively) (Figure 14B-C&16). To assess the effect of 
these mutations on the overall catalytic efficiency of PKM2, we calculated the 
Kcat/Km of 1.83x105, 6.7x104, 2.16x105, and 4.6x104 M-1sec-1 for the WT, MT1, 
MT2, and MT4 enzymes, respectively. Mutations within MT1 and MT4 led to a 
decrease in enzyme efficiency of 60 and 75% compared to WT PKM2, while 
mutations in MT2 caused a 20% increase in Kcat/Km. Surprisingly, combining amino 
acid changes in MT2 and MT4 within MT3, completely abolished any detectable 
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PKM2 function within the LDH-coupled assay. Taken together, these data suggest 
that these amino acid changes can either increase (MT2) or decrease (MT1 and 
MT4) the kinetic activity of PKM2, particularly its catalytic efficiency, while the 
combination of mutations within MT2 and MT4 abolish all activity (MT3). 
Examination of Oligomer States of His-PKM2 Proteins 
PKM2 can exist as a monomer, dimer, and tetramer and these varying 
oligomer states can influence enzymatic activity. As I observed differences in 
enzymatic activity in mutant His-PKM2 proteins, particularly complete loss in MT3, 
I next wanted to determine if the mutations changed the oligomerization of PKM2.  
For this, 50ng aliquots of His-PKM2 enzymes (study performed with proteins 
purified from batch 2) were incubated with disuccinimidyl suberate (DSS), which is 
a non-cleavable, cell permeable protein cross-linker. Enzymes were then 
subjected to SDS-PAGE and immunoblot analysis. Under these conditions, DSS 
cross-linking resulted in the formation of dimer and tetramer states for the PKM2 
enzymes (Figure 17). As a positive control, FBP was added 30 minutes before 
DSS crosslinking, which resulted in greater tetramer formation of WT His-PKM2 
(Figure 17, compare lanes 1 & 8). Cross-linking of His-PKM2 MT3 revealed the 
presence of large molecular weight aggregates (~300kDa) beyond dimer and 
tetramer forms of PKM2. The presence of these aggregates may explain the lack 
of activity of MT3 within the kinetics assay, as aggregation may have limited the 
concentration of potentially active protein within the assay. 





Figure 17.  Cross-linking analysis to assess oligomerization of His-
PKM2 proteins. 50ng aliquots of His-PKM2 WT and MT proteins (Batch 2) 
were cross-linked with DSS (left: 10μM; right: 20μM) as described in the 
materials and methods. Samples were then subjected to SDS-PAGE and 
immunblotted for His. Additional preparations of WT PKM2 without DSS or in 
the presence of DSS and 500μM FBP were performed to define monomer 
PKM2 and assess FBP on tetramer formation, respectively. Shown are 
representative Western blots of two separate experiments. 
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After defining the kinetic activity of His-PKM2 WT, MT1, MT2, MT3, and 
MT4, I next assessed the effect of PSAT1 on the activity of each enzyme. Using  
the kinetic protocol described above, 400nM PSAT1 was incubated with the His-
PKM2 proteins before initiation of the LDH-coupled kinetics assay. Unlike what 
was previously observed in the preliminary studies using untagged PKM2-Sigma, 
I found that addition of PSAT1 was unable to increase the activity of any of the His-  
PKM2 enzymes (Figure 18-22; plots for each enzyme from both batches is shown 
in Figures 29-36 in the Appendix). In addition, there was no significant change in 
the Km for PEP of any of the His-PKM2 proteins in the presence of PSAT1 (Figure 
25).  To ensure that the His-PKM2 enzymes were capable of responding to 
external stimulus, I added 500μM of FBP before initiating the kinetic assays.  For 
all of the active His-PKM2, FBP was found to considerably decrease the Km for 
PEP (Figures 18-22). This shift in Km is not unexpected as this has previously been 
reported for PKM2 and the crosslinking experiments showed an increase in the 
tetrameric state of, at least, His-PKM2 WT, in the presence of FBP (Figure 17). 
These results indicate that, unlike the preliminary data utilizing untagged PKM2-
Sigma within the ADP-glo assay, PSAT1 was unable to increase His-PKM2 
activity, even though these His-tagged enzymes still possessed the ability to be 
activated by FBP.  
Direct Comparison of His-PKM2 and untagged PKM2-Sigma 
To determine whether this discrepancy is due to the use of different assays, I 
directly compared the effect of PSAT1 addition on PKM2-Sigma within both the 
LDH-coupled assay as well as His-PKM2 WT within the ADP-glo. I first performed 
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Western blot analysis to demonstrate that the protein levels of both His-PKM2 and 
PKM2-Sigma were similar, and that PKM2-Sigma does not contain a His-tag 
(Figure 23A).  Analysis of PKM2-Sigma within the LDH-coupled assay determined 
a Vmax of 0.77 nmol / min, similar to that observed with His-PKM2.  Unlike His-
PKM2, upon incubation with PSAT1, PKM2-Sigma exhibited an increase in Vmax 
(0.95 nmol / min), a decrease in the Km to 0.38 mM, and an 2.2 fold increase in 
catalytic efficiency (Figure 23B).  To verify this result and determine whether His-
PKM2 may be stimulated in other assays, I repeated the ADP-glo protocol with 
both His-PKM2 WT and PKM2-Sigma. Similar to that observed with the LDH-
coupled assay, PSAT1 failed to enhance the activity of His-PKM2 compared to 
PKM2-Sigma (Figure 26).  Together these data suggest that while His-PKM2 
proteins maintain enzymatic activity that can be stimulated with known allosteric 
activators, something inherent in these recombinant proteins is precluding 
activation by PSAT1.  Direct comparison with PKM2-Sigma suggests that the 
presence of the His-tag on the His-PKM2 proteins may disrupt the association with 
PSAT1 that is observed with un-tagged PKM2-Sigma.  
ASSESSMENTS FOR INTERACTION BETWEEN WILD-TYPE AND MUTANT 
HIS-PKM2 ENZYMES AND PSAT1 
PSAT1 associates non-specifically to Ni-NTA beads 
To determine whether the His-PKM2 proteins were able to associate with PSAT1, 
I performed a pull-down assay using His-PKM2 WT and Ni-NTA sepharose beads.  
As a negative control, a separate sample was added that contained PSAT1 and 
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Figure 18.  Effect of PSAT1 and FBP on WT His-PKM2 activity. 
Enzymatic activity of WT His-PKM2 (2.5nM) was measured by an enzyme- 
coupled assay with increasing concentrations of PEP in the presence or 
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a 
non-linear regression analysis. Results are an average of two experiments 
using protein preparations from either batch 1 or batch 2 that incorporate two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 
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Figure 19.  Effect of PSAT1 and FBP on MT1 His-PKM2 activity. 
Enzymatic activity of MT1 His-PKM2 (2.5nM) was measured by an enzyme- 
coupled assay with increasing concentrations of PEP in the presence or 
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a 
non-linear regression analysis. Results are an average of two experiments 
using protein preparations from either batch 1 or batch 2 that incorporate two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 
each condition with standard deviation indicated within the parentheses. 
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Figure 20.  Effect of PSAT1 and FBP on MT2 His-PKM2 activity. 
Enzymatic activity of MT2 His-PKM2 (2.5nM) was measured by an enzyme- 
coupled assay with increasing concentrations of PEP in the presence or 
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a 
non-linear regression analysis. Results are an average of two experiments 
using protein preparations from either batch 1 or batch 2 that incorporate two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 





Figure 21.  Effect of PSAT1 and FBP on MT3 His-PKM2 activity. 
Enzymatic activity of MT3 His-PKM2 (2.5nM) was measured by an enzyme- 
coupled assay with increasing concentrations of PEP in the presence or 
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a 
non-linear regression analysis. Results are an average of two separate 
experiments incorporating two technical replicates.  
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Figure 22.  Effect of PSAT1 and FBP on MT4 His-PKM2 activity. 
Enzymatic activity of MT4 PKM2 (2.5nM) was measured by an enzyme- coupled 
assay with increasing concentrations of PEP in the presence or absence of 
PSAT1 or FBP. Data is represented as nmol / min and fitted to a non-linear 
regression analysis. Results are an average of two experiments using protein 
preparations from either batch 1 or batch 2 that incorporate two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
























Figure 23. Kinetic analysis of PKM2-Sigma activity in the presence 
of PSAT1. (A) Representative Western blot comparing purified His-PKM2 WT 
with PKM2-Sigma. 50ng of enzyme was separated by SDS-PAGE and 
immunobloted using His or PKM2 specific antibodies. (B) Enzymatic activity of 
PKM2-Sigma (2.5nM) was measured by enzyme-coupled assay with increasing 
concentrations of PEP in the presence or absence of PSAT1. Data is 
represented as nmol / min and fitted to a non-linear regression analysis. Results 
are an average of two separate experiments incorporating two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
condition with standard deviation indicated within the parentheses. 
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Figure 24. Vmax differences between samples Graph representing the 
differences in Vmax among the recPKM2 in the presence of either PSAT1 or FBP 
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Figure 25. Km differences between samples Graph representing the 
differences in Km among the recPKM2 in the presence of either PSAT1 or FBP 















Figure 26. Alternative analysis of recPSAT1 activation of in-
house and commercial WT PKM2. Both recPKM2 enzymes were 
incubated with increasing concentrations of PSAT1 and pyruvate kinase 
activity was measured by AD-Glo as described in the materials and 
methods. Data at each PSAT1 concentration is represented as average 
% RLU change from activity observed without PSAT1. Shown is mean ± 




were separated by SDS-PAGE and PSAT1 interaction was assessed by Western 
blot.  First, I was able to successfully pull-down His-PKM2 WT from the protein 
mixture (Figure 27A, Lane 2-4; input of His-PKM2 for reference in Lane 5). 
However, while there was a significant level of PSAT1 observed in the His-PKM2 
pull-down sample (Figure 27A, Lanes 2-3; input of PSAT1 for reference in Lane 
1), I also found that PSAT1 appeared to be non-specifically binding to the Ni-NTA 
beads in the absence of His-PKM2 (Figure 27A, lane 6). To ensure that PSAT1 
did not contain an unexpected His-tag that was mediating its binding to the Ni 
beads, I incubated PSAT1 with beads alone and performed Western blot using 
antibodies specific for His- tag or PSAT1. As illustrated in Figure 27B, PSAT1 
does, in fact, interact with Ni-NTA bead matrix and does so without a His-tag, as 
the anti-His Western blot failed to show any PSAT1 in samples containing PSAT1 
and Ni-NTA. Together, these data suggest that use of Ni-NTA pulldown protocol is 
not compatible to assess PKM2:PSAT1 interaction due to PSAT1’s non-specific 
binding to the nickel beads.  
Co-immunoprecipitation of PSAT1 and PKM2 
Due to the complications that were seen using PSAT1 and Ni-NTA, I decided to 
perform co-immunoprecipitation analysis to examine the interaction with PSAT1  
and WT or MT His-PKM2 proteins.  This approach was used to demonstrate the 
selective association of PSAT1 with un-tagged PKM2-Sigma within the preliminary 
studies.  Immunoblot analysis for PSAT1 demonstrated that the anti-PSAT1 
antibody was able to significantly precipitate PSAT1 from the protein mixture 
(Figure 28, compare lanes 1-5 to lanes 6-10 for IgG control). However, Western 
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blot for His-tagged PKM2 failed to show any enrichment of the His-PKM2 proteins 
with precipitation of PSAT1 (Figure 28). These indicate that unlike PKM2-Sigma 
that was found to directly interact with PSAT1, His-PKM2 enzymes fail to associate 
with PSAT1. While it is unclear as to why these enzymes fail to interact with PSAT1 
(certain hypothesis will be discussed below), these data may explain the lack of 
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Figure 27. Analysis of PSAT1:PKM2 interaction using His-PKM2 
pulldown with Ni-NTA. (A) 50ng of His-PKM2 WT was incubated with 500ng 
of PSAT1. Ni-NTA beads were used to pulldown complex and elutions were 
analyzed by immunoblot analysis. Shown is representative Western blot using 
specific His (PKM2) or PSAT1 antibodies. Input lanes have been labeled in 
addition to lane numbers.  (B) PSAT1 was incubated with Ni-NTA alone and 














    
Figure 28. Co-IP of recombinant PSAT1 and PKM2. Co-IP analysis was 
done on mixture of PSAT1 (50ng) and 500ng of His-PKM2 proteins. Co-IP was 
performed using anti-PSAT1 or normal rabbit IgG (negative control). Shown is a 




CHAPTER FOUR: DISCUSSION 
The goal of this project was to define the consequence of PSAT1 
association on the enzymatic activity of PKM2. This was based on preliminary 
studies that performed mass spectrophotometry on PSAT1 to identify novel 
binding partners and found PKM2 among the list of possible interacting proteins.  
Through an ADP-Glo kinase assay it was shown that addition of PSAT1 led to 
increased PKM2-Sigma activity.  Further, site-directed mutations identified specific 
amino acids that suggested contribution to the interaction between both proteins.  
These findings led to my hypothesis that the direct association of PSAT1 was 
necessary for PKM2 activation and that loss of interaction between PSAT1 and 
PKM2 due to these PKM2 mutations would prevent PSAT1 activation of PKM2.  I 
aimed to test this hypothesis by defining the activity of WT and MT forms of PKM2, 
determining the effect of PSAT1 on their activity, and assessing their interaction 
with PSAT1. To initiate these experiments, I first needed to express and purify 
recombinant proteins by incorporation of a fusion tag.   
Tags encoded by expression vectors differ in their size and the matrix that 
is used to purify the fusion proteins.  Included among these are histidine and GST 
tags that can be purified using nickel or glutathione-linked sepharose, respectively. 
Experimental end-point, as well as effects on the solubility of the fusion protein, 
are factors to be considered when selecting a specific tag.  PKM2 can be 
challenging to express recombinantly, but others have reported that the inclusion 
of a GST tag assists in proper protein folding [73]. Thus, I began by sub-cloning 
the cDNAs encoding WT, MT1, MT2, and MT3 PKM2 into a pGEX4T-1 vector.  
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After cloning, GST-PKM2 was purified under non-denaturing ionic conditions, as 
others have demonstrated that this method increases protein yield [72].  Initial 
attempts utilizing this Sarkosyl:Triton X100 procedure resulted in no GST-PKM2 
purification (Figure 9), leading me to optimize my expression protocols (different 
lysing methods) to obtain significant yield (Figure 10).   
One potential issue with using fusion-tagged proteins is the effect of the tag 
on the activity of the enzyme. Using an enzyme-coupled assay to measure PKM2 
activity, I found that the GST-PKM2 WT and MT proteins displayed no pyruvate 
kinase activity (Figure 10). As I had performed the preparation protocol under non-
denaturing conditions and Coomassie staining revealed little to no contaminating 
proteins, I concluded that the large GST tag was inhibiting enzymatic activity. The 
lack of activity could be potentially due to either changing the overall structure of 
PKM2, preventing oligomerization, or inhibiting substrate binding. In order to 
remove the tag, I decided to utilize the thrombin cleavage site that is encoded 
between the GST tag and PKM2.  However, no PKM2 protein was recovered 
following thrombin cleavage; making it unfeasible to assess enzyme activity.  Due 
to these experimental issues, I decided use a separate expression system to purify 
the WT and MT PKM2 proteins. 
Purification using a His-fusion expression system has been shown to result 
in active pyruvate kinase [55]. After optimizing the purification protocol (Figure 13), 
I was able to produce active His-PKM2, as assessed in the LDH-coupled assay. 
The calculated specific activity of my purified His-PKM2 WT (55 μmol / min / mg), 
which is half of what has been previously published by others (116 μmol / min / 
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mg) [47].  As point mutations have been previously reported to alter PKM2 activity 
[55], I proceeded to define the kinetics of all four mutant His-PKM2 forms.  
In my studies, the introduction of the separate mutations resulted in different 
kinetics for His-PKM2. While mutations in MT1 did not appear to alter activity 
compared to WT; MT2 His-PKM2 demonstrated an increase in Vmax. Yet, these 
amino acid changes within MT2 did not significantly alter the Km for PEP.  This 
suggests that these mutations may modify the protein structure in such a way as 
to distort the active site, resulting in lower activation energy and increased pyruvate 
formation. Conversely, MT4 exhibited a slight decrease in Vmax, indicating that 
these mutations negatively affect enzyme activity. However, amino acid changes 
in MT3 His-PKM2 entirely abolished pyruvate kinase activity.   
 The complete lack of activity is surprising in that MT3 is a combination of 
mutations found in MT2 and MT4 His-PKM2.  As other site-specific mutations have 
previously been shown to affect dimer/tetramer formation of PKM2, cross-linking 
studies were done to assess effects on the oligomerization of His-PKM2. I found 
that MT3 forms high molecular weight aggregates under native conditions 
compared to WT and other MT His-PKM2 proteins. From this, it still needs to be 
determined whether these mutations abolish activity due to inducing His-PKM2 
misfolding and aggregation.  The cross-linking experiments also showed that there 
were no adverse effects on dimer/tetramer formation between WT, MT1, MT2, or 
MT4 suggesting that the differences observed in activity may not be a result of 
changes in oligomer formation.  
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Next, I determined the effect of PSAT1 on the activity of all forms of His-
PKM2. While the preliminary studies demonstrate that PSAT1 stimulates PKM2-
Sigma, PSAT1 failed to activate any of the His-PKM2 proteins. To determine 
whether these enzymes respond to other activators, I added FBP and observed 
either significant increases in enzyme activity, lowering of Km for PEP, or both as 
has been previously described for FBP.  This is supported, at least with His-PKM2 
WT, that addition of FBP leads to greater tetramer formation, which is well 
established to increase PKM2 activity. Lastly, to determine whether it was a 
difference in assays that were leading to the discrepancy in the ability of PSAT1 to 
activate His-PKM2, I repeated both the LDH-coupled assay and the ADP-Glo using 
both PKM2-Sigma and His-PKM2 WT.  I observed that PSAT1 was able to 
stimulate PKM2-Sigma in both assays, while His-PKM2 WT failed to show any 
increase. Together, these data suggest that the His-tag on the PKM2 enzymes 
was inhibiting the transactivation potential of PSAT1, potentially through blocking 
the association between PSAT1 and the His-PKM2 proteins. 
Since the preliminary data suggested that PSAT1’s interaction with PKM2-
Sigma allows for activation, I performed association studies to determine the amino 
acid requirement for PSAT1:PKM2 interaction. However, I was unable to observe 
interaction with any of the active His-PKM2 enzymes.  Both Ni-NTA pulldown and 
co-immunoprecipitation studies demonstrated a lack of specific interaction 
between PSAT1 and His-PKM2. Attempting to pull-down PSAT1 using His-
PKM2:Ni-NTA chromatography proved to be ineffective, as PSAT1 was found to 
bind non-specifically to the nickel beads. Also, co-immunoprecipitation analysis 
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using a PSAT1 antibody, similar to that used in the preliminary studies with PKM2-
Sigma, failed to enrich levels of His-PKM2 above that of the IgG negative control. 
Together, my interaction experiments suggest that His-PKM2 proteins are unable 
to associate with PSAT1. While not conclusive, this could explain the lack of 
activation of His-PKM2 upon addition of PSAT1.  
As demonstrated by Western blot, PKM2-Sigma does not contain a His-tag.  
While unexpected, cumulatively, my data indicate that the His-tag within the His-
PKM2 enzymes is affecting the interaction with PSAT1. Yet, another possible 
reason relates to potential differences in the purification scheme used to produce 
both the PKM2-Sigma and His-PKM2 proteins.  Buffers used to lyse, wash, elute, 
and even dialyze PKM2 could lead to differences in the ability to interact with 
PSAT1.  A shift in pH between two separate buffers could be a determining factor 
as to whether proteins associate.  Lastly, PSAT1 requires a co-factor, PLP, for its 
enzymatic activity and in theory optimal tertiary structure. I did not add this co-
factor to either the His-PKM2 enzymatic or associating assays. However, I do not 
believe that this contributed to the lack of effect, as the preliminary data using 
PKM2-Sigma also did not add exogenous PLP. 
Future studies related to this project should be focused on identifying other 
purification schemes to purify the PKM2 enzymes. As thrombin cleavage was 
inefficient in obtaining PKM2 enzymes, cDNA can be sub-cloned into other GST-
fusion vectors that contain cleavage sites for other enzymes, such as PreScission 
Protease. As informative as these results are regarding the kinetic characteristics 
of WT and MT His-PKM2 proteins, the question persists of what region/amino 
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acids of PKM2 is required for binding to PSAT1.  Importantly, while the preliminary 
data suggest that amino acids that make up MT3 aid in disassociating PSAT1, they 
may lead to overall structural changes in PKM2 and may not be directly involved 
in the interaction with PSAT1. This could also be addressed through computational 
programs, such as the Rosetta Online Server that Includes Everyone (ROSIE). 
ROSIE uses a Monte Carlo based algorithm to predict the likelihood of two 
proteins interacting with one another using its structure-prediction based program 
[71].  Although ROSIE is capable of prediction protein: protein interaction, separate 
tools must be used to prepare the proteins of interest structure for ROSIE docking.  
Protein structures, attained in the form of protein data banks (PDB) files, are 
loaded into separate computer software for molecular visualization such as PyMol 
or Chimera.  Within the software, users are capable of manipulating the protein 
structure through the removal, addition, or replacement of amino acids.  When 
investigating possible protein: protein interaction, it is crucial that the regions that 
are believed to have a role in the interaction be positioned nearby one another.  
The purpose of this positioning becomes apparent when simulating protein: protein 
interaction through ROSIE, which performs local docking on the given starting 
conformation of the proteins involved.  The resulting output from ROSIE is a list of 
possible protein conformations with the 10 lowest-energy needed structures being 
prominently displayed. 
As these two proteins play essential roles in tumor metabolism, ultimately 
characterizing their functional association in the context of changing glucose 
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and/or serine metabolism will provide a more comprehensive understanding of 
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Figure 29.  Effect of PSAT1 and FBP on WT His-PKM2 (Batch1) 
activity. Enzymatic activity of WT PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme- coupled assay with increasing concentrations of PEP in the 
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and 
fitted to a non-linear regression model. Results are an average of two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
condition. SD is indicated within the parentheses.   
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Figure 30.  Effect of PSAT1 and FBP on MT1 His-PKM2 (Batch1) 
activity. Enzymatic activity of MT1 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and 
fitted to a non-linear regression model. Results are an average of two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
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Figure 31. Effect of PSAT1 and FBP on MT2 His-PKM2 (Batch1) 
activity. Enzymatic activity of MT2 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and 
fitted to a non-linear regression model. Results are an average of two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
condition. SD is indicated within the parentheses.   
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Figure 32. Effect of PSAT1 and FBP on MT4 His-PKM2 (Batch 1) 
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min 
and fitted to a non-linear regression model. Results are an average of two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 
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Figure 33. Effect of PSAT1 and FBP on WT His-PKM2 (Batch 2) 
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min 
and fitted to a non-linear regression model. Results are an average of two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 
each condition. SD is indicated within the parentheses 
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Figure 34. Effect of PSAT1 and FBP on MT1 His-PKM2 (Batch 2) 
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min 
and fitted to a non-linear regression model. Results are an average of two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 
each condition. SD is indicated within the parentheses 
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Figure 35. Effect of PSAT1 and FBP on MT2 His-PKM2 (Batch 2) 
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and 
fitted to a non-linear regression model. Results are an average of two technical 
replicates. Table depicts average kinetic parameters (Vmax and Km) for each 
condition. SD is indicated within the parentheses 
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Figure 36. Effect of PSAT1 and FBP on MT4 His-PKM2 (Batch 2) 
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured 
by an enzyme-coupled assay with increasing concentrations of PEP in the 
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min 
and fitted to a non-linear regression model. Results are an average of two 
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for 




PKM2 Pyruvate Kinase M2 isoform 
PSAT1 PhosphoSerine AminoTransferase 1 
recPKM2 Recombinant PKM2 protein 
ATP Adenosine TriPhosphate 
HK Hexokinase 
G6P Glucose 6-Phosphate 
PGI PhosphoGlucose Isomerase 
F6P Fructose 6-Phophate 
PFK1 PhosphoFructoKinase-1 
FBP Fructose 1,6-BisPhosphate 




NAD Nicotinamide Adenine Dinucleotide 
ADP Adenosine DiPhosphate 
PEP PhosphoEnolPyruvate 
PK Pyruvate Kinase 
TCA TriCarboxylic Acid 
FAD Flavin Adenine Dinucleotide 
LDH Lactate DeHydrogenase 
FDG FluroDeoxyGlucose 
PET Positron Emission Tomography 
CT Computed Tomography 
HIF1⍺ Hypoxia Inducing Factor 1 ⍺ 
PPP Pentose Phosphate Pathway 
NADP 
Nicotinamide Adenine Dinucleotide 
Phosphate 
ROS Reactive Oxygen Species 
PHP 3-PhosphoHydroxyPyruvate 
PHGDH PHosphoGlycerate DeHydrogenase 
PLP PyridoxaL 5'-Phosphate 
⍺KG ⍺-KetoGlutarate 
P-ser PhosphoSERine 
PSPH PhosphoSerine PHosphatase  
THF TetraHydroFolate 
SAM S-Adenosyl Methionine 
hnRNP HeterogeNous RiboNucleoProteins 
SRSF 3 Serine-aRgenine Splice Factor 3 
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H3T11 Tyrosine 11 on Histone H3 
mTHF methyl TetraHydroFolate 
MT1 Mutant 1 
MT2 Mutant 2 
MT3 Mutant 3 
MT4 Mutant 4 
WT Wild-Type 
B.1 Batch 1 
B.2 Batch 2 
 
  Table 1.  Abbreviations 
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Assessment of interaction of His-PKM2 with Glutathione Beads 
 The PSAT1:PKM2 association was originally identified through a GST-
PSAT1 pulldown. To determine the feasibility of this strategy to investigate His-
PKM2 association, I first wanted to test if His-PKM2 non-specifically bound to 
glutathione beads. For this, 0.1% of BSA was added to Glutathione beads and 
incubated overnight at 4oC.  500ng of His-PKM2 was added to the solution and 
incubated at 4oC for an additional 45 minutes.  Beads were centrifuged, and 
supernatant was discarded.  Beads were washed 3 times using 1x PBS, 
centrifuged, and supernatant was discarded.  25L of 1x Laemmli Buffer was 
added to the beads and heated to 95oC for 5 minutes.  Beads were then 
centrifuged, and supernatant was loaded onto 10% SDS-PAGE gel. Binding of His-
PKM2 to glutathione beads was assessed by immunoblotting using anti-His 
antibody. As depicted in Figure 37, no His-PKM2 was seen bound to GST beads.  
These data suggest that binding of His-PKM2 protein to GST-PSAT1 may be 






Figure 37.  Analysis of His-PKM2 association with glutathione beads. 
His-tagged PKM2 proteins were incubated with glutathione beads alone. Elutions 
were ran on SDS-PAGE and shown is an individual Western blot assessing 
presence of PKM2 using an anti-His antibody. Aliquot of recPKM2 WT was used 
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